T-knife Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

T-knife Therapeutics is a San Francisco-based biopharmaceutical company focused on developing novel cancer therapeutics, primarily T cell receptor (TCR) engineered T cell therapies (TCR-Ts). The company uses its HuTCR mouse platform, a discovery engine that yields fully human tumor-specific TCRs selected in vivo for optimal affinity and high specificity. It is advancing a portfolio of TCR-T product candidates targeting high unmet medical needs, including cancer testis antigens, oncoviral antigens, and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbrück Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. The organization has 11 to 50 employees and is headquartered in San Francisco, California. Recent updates include the authorization of a Clinical Trial Application to begin the Phase 1 ATLAS trial of TK-6302 in Europe, and reports of ongoing Phase 1 testing of a CRISPR T cell therapy.

Sign up for free to view info

Company overview Employee directory